12:05 PM EST - Biovail Corp. : tumbled 16.25 percent after the Toronto-based drugmaker failed to win approval from the U.S. Food and Drug Administration for its once-daily formulation of anti-smoking drug and antidepressant bupropion. Biovail Corp.
shares T.BVF are trading off 16.25 percent at $22.27.
